Corcept Therapeutics Incorporated
General ticker "CORT" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $7.1B (TTM average)
Corcept Therapeutics Incorporated follows the US Stock Market performance with the rate: 0.3%.
Estimated limits based on current volatility of 2.4%: low 34.19$, high 35.86$
Factors to consider:
- Total employees count: 500 (+42.0%) as of 2024
- Top business risk factors: Pandemic risks, Insufficient funding, Labor/talent shortage/retention, Regulatory and compliance, Political instability
- Current price 41.8% below estimated low
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [58.44$, 91.31$]
- 2026-12-31 to 2027-12-31 estimated range: [58.50$, 92.05$]
Financial Metrics affecting the CORT estimates:
- Negative: with PPE of 93.4 at the end of fiscal year the price was high
- Positive: -4.75 < Operating profit margin, % of 5.88
- Negative: negative Industry operating income (median)
- Positive: Return on assets ratio (scaled to [-100,100]) of 10.64 > 6.11
- Positive: Inventory ratio change, % of -0.14 <= 0
- Positive: 0.01 < Operating cash flow per share per price, % of 1.79
- Positive: Interest expense per share per price, % of 0 <= 0.01
- Positive: Industry inventory ratio change (median), % of 0 <= 0
Short-term CORT quotes
Long-term CORT plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $482.38MM | $675.04MM | $761.41MM |
| Operating Expenses | $375.09MM | $538.09MM | $716.61MM |
| Operating Income | $107.28MM | $136.95MM | $44.80MM |
| Non-Operating Income | $17.27MM | $24.54MM | $21.67MM |
| R&D Expense | $184.35MM | $246.89MM | $254.91MM |
| Income(Loss) | $124.56MM | $161.49MM | $66.46MM |
| Taxes | $18.42MM | $20.28MM | $-33.19MM |
| Profit(Loss)* | $106.14MM | $139.73MM | $101.13MM |
| Stockholders Equity | $506.70MM | $679.59MM | $647.80MM |
| Inventory | $7.73MM | $12.41MM | $12.87MM |
| Assets | $621.52MM | $840.55MM | $836.65MM |
| Operating Cash Flow | $127.04MM | $198.07MM | $142.00MM |
| Capital expenditure | $0.14MM | $2.17MM | $0.21MM |
| Investing Cash Flow | $90.91MM | $-177.60MM | $69.76MM |
| Financing Cash Flow | $-148.72MM | $-28.35MM | $-220.37MM |
| Earnings Per Share** | $1.02 | $1.35 | $0.97 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.